Corona Remedies Limited IPO
Corona Remedies Limited was a mainboard IPO in the Pharmaceuticals sector, offered at ₹1,008–₹1,062 per share to raise ₹655 crore. The issue was subscribed 137.04× overall (QIBs 278.52×, NIIs 208.88×, retail 28.73×). It listed on 15 Dec 2025 at ₹1,470 and closed its first day at ₹1,438, a listing gain of +35.4% versus the ₹1,062 issue price. It now trades around ₹2,150 (+102.4% versus the issue price).
Frequently asked questions
- How many times was the Corona Remedies Limited IPO subscribed?
- The Corona Remedies Limited IPO was subscribed 137.04× overall — 278.52× in the QIB category, 208.88× among non-institutional investors, 28.73× in retail.
- What were the Corona Remedies Limited IPO listing gains?
- Corona Remedies Limited listed on 15 Dec 2025 at ₹1,470, closing its first day at ₹1,438 — a listing gain of +35.4% versus the ₹1,062 issue price.
- What were the retail allotment odds for the Corona Remedies Limited IPO?
- Retail was subscribed 28.73×, so a single-lot application had roughly a 3.5% chance of allotment (about 1 in 29), and allotment was finalised on 11 Dec 2025.
- What was the price band and lot size of the Corona Remedies Limited IPO?
- The price band was ₹1,008–₹1,062 per share, with a minimum lot of 14 shares (₹14,868 at the upper band).
- Who were the registrar and lead manager for the Corona Remedies Limited IPO?
- Bigshare Services Private Limited was the registrar, and JM Financial was the book-running lead manager.